Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Debt: 2016-2018

  • Niagen Bioscience's Total Debt fell 55.81% to $137,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $137,000, marking a year-over-year decrease of 55.81%. This contributed to the annual value of $137,000 for FY2018, which is 55.81% down from last year.
  • As of Q4 2018, Niagen Bioscience's Total Debt stood at $137,000, which was down 55.81% from $310,000 recorded in Q4 2017.
  • Niagen Bioscience's Total Debt's 5-year high stood at $4.9 million during Q1 2016, with a 5-year trough of $137,000 in Q4 2018.
  • Its 3-year average for Total Debt is $1.4 million, with a median of $327,000 in 2016.
  • Data for Niagen Bioscience's Total Debt shows a maximum YoY slumped of 92.94% (in 2016) over the last 5 years.
  • Quarterly analysis of 3 years shows Niagen Bioscience's Total Debt stood at $344,000 in 2016, then fell by 9.88% to $310,000 in 2017, then slumped by 55.81% to $137,000 in 2018.
  • Its Total Debt stands at $137,000 for Q4 2018, versus $310,000 for Q4 2017 and $344,000 for Q4 2016.